Effective Data Management Strategy and Aggressive Investment Approach Found as Biggest Differentiators
NEW YORK, Nov. 8, 2024 /PRNewswire/ -- IBM (NYSE: IBM) released a new report called AI in Action that highlights artificial intelligence strategies of businesses considered "AI Leaders." The report is based on a survey, conducted on behalf of IBM by Harris Poll, of 2,000 companies across the U.S., U.K., India, Japan and Germany.
According to the findings, of the 2,000 businesses surveyed, 15% reported being far ahead of their peers when it comes to leveraging AI to maximize value across their business. The report defines these businesses as "AI Leaders." The remaining 85% of respondents were classified as "Learners."
"Of the organizations that were considered AI Leaders, two-thirds reported that AI has already driven 25% or greater improvement in their revenue growth rate," said Shobhit Varshney, VP & Sr. Partner, Americas AI Leader, IBM Consulting. "We dove into the data to uncover how these AI Leaders were implementing AI within their businesses that could help others learn from their success."
The report identified four key findings that may explain the outcomes achieved by AI Leaders:
For the full report, including country-specific data, visit https://www.ibm.com/think/reports/ai-in-action. Is your company an AI Leader? Click HERE to take the quiz and find out.
The research for this report was conducted online by The Harris Poll on behalf of IBM from 20 February through 24 April 2024. The survey was conducted among IT and business decision-makers in the US, Japan, Germany, the UK and India. The decision-makers had to possess a deep knowledge of their company's AI-based tools or processes in all their forms and work for large companies with either an annual revenue of more than USD 500 million or a company size of more than 1,000 employees.
About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service.
About The Harris Poll
The Harris Poll is one of the longest-running market research firms in the US, tracking public opinion, motivations and social sentiment since 1963. It's now part of Harris Insights & Analytics, a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. It works with clients in 3 primary areas: building a 21st-century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. Its mission is to provide insights and advisory to help leaders make the best decisions possible.
Media contact:
Rebecca Neufeld
rebecca.neufeld@ibm.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
IBM "AI in Action" Report Identifies Key Characteristics of Businesses That Consider Themselves Leaders in AI
Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving pembrolizumab
SEOUL, South Korea, Nov. 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced groundbreaking research findings demonstrating the potential of its AI to predict immunotherapy treatment outcomes in rare tumors. Conducted in collaboration with The University of Texas MD Anderson Cancer Center, this study will be presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, held November 6-10 in Houston, Texas. Accepted as a Rapid Oral presentation, the study will be presented by Mohamed Derbala, M.D., a research scientist at MD Anderson. It has also been selected as one of the SITC TOP 100 abstracts, underscoring its potential significance and impact in the field of immunotherapy.
Immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab, has emerged as a revolutionary treatment option for cancer patients. However, not all patients respond equally to this treatment, and predicting who will benefit most has been a significant challenge, especially in rare tumor types where treatment options and research data are limited.
Led by principal investigator Dr. Aung Naing, professor of Investigational Cancer Therapeutics at MD Anderson, the research utilized Lunit's AI-powered whole-slide image analyzer, Lunit SCOPE IO®, to assess tumor microenvironment characteristics in both pre-treatment and on-treatment biopsies from patients with rare tumors receiving pembrolizumab. The study analyzed over 500 slides across more than 10 different rare tumor types.
The findings indicate that Lunit SCOPE IO could effectively identify specific patterns in tumor samples that correlate with better treatment outcomes. The research showed that patients whose tumor samples displayed AI-detected changes in both intratumoral immune cell (intratumoral tumor-infiltrating lymphocyte; iTIL) presence and tumor content, were significantly more likely to have better treatment outcomes positively to immunotherapy treatment.
Key findings from the study include:
"These findings highlight how our AI technology can provide deep insights into the unique and challenging tumor microenvironment seen in rare cancers, and represent a critical advancement in our understanding of rare tumor biology," said Brandon Suh, CEO of Lunit. "This study has demonstrated the value of Lunit SCOPE IO in an important clinical setting, showcasing its potential to personalize treatment for patients who have limited therapeutic options. We believe these advancements are a testament to the transformative impact AI can have on oncology and patient outcomes."
By expanding the capabilities of Lunit SCOPE IO, Lunit aims to continue partnering with leading cancer research institutions to deliver innovative and meaningful solutions for patients with limited treatment options, ultimately transforming cancer care.
For more details about the study and its findings, please visit Lunit's booth #317 at the SITC 2024 Annual Meeting.
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer. We harness AI-powered medical image analytics and AI biomarkers to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,500 hospitals and medical institutions across 55+ countries.
Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as ASCO and RSNA. In 2024, Lunit acquired Volpara Health Technologies, setting the stage for unparalleled synergy and accuracy, particularly in breast health and screening technologies. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024
